Comparison
5q14 3 Microdeletion Syndrome C4304529 vs 2 Hydroxyglutaric Aciduria C2746066
Clinical comparison between 5q14 3 Microdeletion Syndrome and 2 Hydroxyglutaric Aciduria for differential diagnosis and treatment planning.
5q14 3 Microdeletion Syndrome C4304529
A rare genetic condition involving deletion of a small region on chromosome 5, affecting brain development and often causing seizures and developmental issues.
2 Hydroxyglutaric Aciduria C2746066
An organic acidemia where elevated acids accumulate in the body. It can cause neurological and developmental problems. Treatment focuses on supportive care and symptom management.
6 comparison axes
Onset
5q14 3 Microdeletion Syndrome C4304529
Variable
2 Hydroxyglutaric Aciduria C2746066
0-10
Onset patterns differ
Severity
5q14 3 Microdeletion Syndrome C4304529
severe
2 Hydroxyglutaric Aciduria C2746066
moderate
Different severity levels
Chronic
5q14 3 Microdeletion Syndrome C4304529
Chronic
2 Hydroxyglutaric Aciduria C2746066
Chronic
Differing course
Communicable
5q14 3 Microdeletion Syndrome C4304529
No
2 Hydroxyglutaric Aciduria C2746066
No
Different transmission
Body System
5q14 3 Microdeletion Syndrome C4304529
congenital
2 Hydroxyglutaric Aciduria C2746066
metabolic
Same/different system
Category
5q14 3 Microdeletion Syndrome C4304529
genetic
2 Hydroxyglutaric Aciduria C2746066
metabolic
Different category
Bottom line
5q14-3-microdeletion-syndrome-C4304529 and 2-hydroxyglutaric-aciduria-C2746066 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 5q14 3 Microdeletion Syndrome C4304529 | 2 Hydroxyglutaric Aciduria C2746066 | Discriminating power |
|---|---|---|---|
| Developmental problems | Often linked to impaired brain development from a 5q14.3 deletion. | May occur with accumulation of 2-hydroxyglutaric acid. | Moderate |
| Seizures | Frequently described, although seizure type and frequency are not established here. | Possible neurologic feature, but not established as defining from these data. | Low |
| Metabolic abnormality | Not described as an organic acidemia. | Characterized by elevated organic acids, without a numeric cutoff supplied. | High |
When to favor each condition
Choose 5q14 3 Microdeletion Syndrome C4304529 when
A chromosomal test identifies a 5q14.3 deletion.
This directly supports the genetic condition rather than an organic acidemia.
High
Congenital neurodevelopmental features occur without metabolic evidence.
The supplied profile is congenital and genetic, but absence of one result is not definitive.
Moderate
Onset is variable and severity appears severe.
These axes favor the microdeletion, though they do not confirm it.
Moderate
Choose 2 Hydroxyglutaric Aciduria C2746066 when
Organic-acid testing shows elevated 2-hydroxyglutaric acid.
This supports the metabolic diagnosis; the exact cutoff is not supplied.
High
Neurologic problems begin in childhood, from birth to age 10.
The supplied onset axis fits this condition better than variable onset.
Moderate
Care centers on metabolic monitoring and symptom support.
The description emphasizes supportive management rather than a chromosomal deletion.
Moderate
How key tests differ
| Test | 5q14 3 Microdeletion Syndrome C4304529 | 2 Hydroxyglutaric Aciduria C2746066 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or equivalent genetic test | May show deletion involving 5q14.3. | Not expected to establish this metabolic condition. | A confirmed deletion supports the left diagnosis; clinical correlation remains necessary. |
| Urine or plasma organic-acid analysis | No characteristic organic acidemia is described. | Elevated 2-hydroxyglutaric acid may be found; no cutoff is supplied. | An abnormal result suggests the right condition but requires clinician confirmation. |
| Neurologic assessment, EEG, or brain imaging | May show seizure-related or developmental abnormalities. | May also be abnormal because of neurologic involvement. | Findings can overlap and do not by themselves distinguish the conditions. |
Prognosis comparison
5q14 3 Microdeletion Syndrome C4304529
- Outcome
- Often a chronic, potentially severe neurodevelopmental course; exact outcomes are not established.
- Factors
- Deletion findings, seizures, developmental needs, and available support may influence course.
2 Hydroxyglutaric Aciduria C2746066
- Outcome
- A chronic metabolic condition with variable neurologic impact; mortality is not established.
- Factors
- Metabolic abnormalities, neurologic complications, and supportive care may influence course.
Time frame: Generally lifelong; onset is variable on the left and often from birth to age 10 on the right.
Etiology, severity, seizures, developmental impairment, and access to coordinated care.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental disability | Often a major, potentially severe feature. May occur, with severity not precisely established here. Both can affect development; comparative outcomes are not quantified. |
| Seizures | Commonly reported with the microdeletion. Possible but not established as characteristic from the source. Seizure burden should be assessed individually. |
| Metabolic imbalance | Not a described feature. Acid accumulation is central, but crisis frequency is not supplied. Do not infer emergency thresholds or treatment doses from these data. |
Patient education highlights
- HighResult versus diagnosis
An abnormal genetic or metabolic result needs clinician interpretation and does not alone complete the diagnosis.
- HighDifferent causes
One condition is a chromosomal deletion; the other is a metabolic organic acid disorder.
- MediumSupportive care
Management is individualized. No treatment dose or guaranteed outcome is established here.